NexImmune, Inc. (NEXI)

Market Cap	139.00 -50.2%
Revenue (ttm)	n/a
Net Income	-20.62M
EPS	-17.39
Shares Out	1.39M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	100
Open	0.0002
Previous Close	0.0001
Day's Range	0.0001 - 0.0002
52-Week Range	0.000001 - 2.1700
Beta	4.28
Analysts	n/a
Price Target	n/a
Earnings Date	n/a

About NexImmune

NexImmune, Inc., a clinical-stage biotechnology company, engages in developing therapies with curative potential for patients with cancer and other life-threatening immune-mediated diseases in the United States. It develops approaches to T cell immunotherapies based on its proprietary Artificial Immune Modulation, a vivo directly injectable modality platform. The company’s product candidates include NEXI-001, an allogeneic cell therapy, which is in Phase I/II clinical trials for the treatment of patients with acute myeloid leukemia; NEXI-002, a...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2011
• Employees: 6
• Stock Exchange: OTCMKTS
• Ticker Symbol: NEXI

Financial Performance

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Aug 26, 2026

Data Sources Report a data error